Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of RAY1216 (Leritrelvir) in Healthy Adults
NCT05829551Phase 1Completed
- Sponsor
- Raynovent Biotech
- Start
- May 2022
- Primary completion
- Aug 2022
- Modality
- Covalent Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of leritrelvir in coronavirus disease 2019 (COVID-19), sponsored by Raynovent Biotech. Primary endpoints: Number and severity of participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAE) in single ascending dose, Number and severity of participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAE) in multiple ascending dose and 2 more. Started May 2022; status: completed.
02
Drugs
leritrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05829551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05829551.